FIELD: chemistry; biotechnology.
SUBSTANCE: invention relates to biochemistry, in particular to an isolated CD45RC antibody or its binding fragment. Also disclosed is a nucleic acid coding said antibody; an expression vector containing said nucleic acid; host cell containing said vector. Disclosed are the use of said antibody for inducing immune tolerance in a subject in need thereof or suppressing transplant rejection; use of said antibody for preventing or treating graft-versus-host disease; method for in vitro detection or quantification using said antibody.
EFFECT: invention provides effective suppression of transplant rejection.
17 cl, 13 ex, 8 tbl, 10 dwg
| Title | Year | Author | Number |
|---|---|---|---|
| ANTI-SIRPα ANTIBODIES | 2018 |
|
RU2771174C2 |
| SCLEROSTIN ANTIBODY, ITS ANTIGEN-BINDING FRAGMENT AND MEDICAL APPLICATION | 2016 |
|
RU2716101C2 |
| NOVEL ANTIBODIES TO BSSL | 2020 |
|
RU2826992C2 |
| ANTIBODIES SUITABLE FOR PASSIVE IMMUNIZATION AGAINST INFLUENZA, AND COMPOSITIONS THEREOF, COMBINATIONS AND METHODS OF USING | 2015 |
|
RU2720282C1 |
| CANCER-RELATED IMMUNOSUPPRESSION INHIBITOR | 2018 |
|
RU2805232C2 |
| METHODS FOR TREATMENT OF SEVERE INSULIN RESISTANCE BY INTERRUPTING GLUCAGON RECEPTOR SIGNAL TRANSMISSION | 2017 |
|
RU2772508C2 |
| IMMUNOCYTOKINES BASED ON IL-15 AND IL-15Rα OF THE SUSHI DOMAIN | 2012 |
|
RU2763298C2 |
| USE OF THE ANTI-O-ACETYLATED GANGLIOSIDE GD2 ANTIBODY FOR IMPROVING THE THERAPEUTIC POTENTIAL OF DRUGS | 2017 |
|
RU2771173C2 |
| ANTIBODY TO B7-H4, ITS ANTIGEN-BINDING FRAGMENT AND ITS PHARMACEUTICAL USE | 2019 |
|
RU2792748C2 |
| GREMLIN-1 INHIBITOR FOR THE TREATMENT OF BONE FRACTURE OR BONE DEFECT | 2019 |
|
RU2790992C2 |
